By Dr Ronald DePinho (UT MD Anderson Cancer Center)2024-08-02T10:00:43
In this Q&A, Dr Ronald DePinho of MD Anderson elucidates their preclinical proof-of-concept that adjusting TERT levels could be a viable therapeutic approach for mitigating age-related diseases, such as cancer, heart disease and Alzheimer’s.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-07-10T09:00:00Z
2026-07-10T06:15:00Z
Contributor Professor Donald E Ingber, By Drug Target Review
2026-07-08T12:00:00Z
2024-01-10T08:23:16
Sponsored by BellBrook Labs
2023-02-23T14:02:18
Sponsored by bit.bio
2023-03-28T11:38:32
Sponsored by Bio-Techne
2024-01-09T10:09:08
Sponsored by Sartorius iQue®
2025-08-05T13:42:00
Sponsored by ICON plc., By Drug Target Review
2025-05-14T14:30:00
Sponsored by Abzena
Site powered by Webvision Cloud